Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...

SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...

Think of training, communication and community as the three vertices of a triangle. Lose any one, and the structure collapses ...

Opening a business credit card is often framed as a way to separate expenses and earn basic rewards, but the real value can ...

These recommendations will consider the hockey experiences needed for developing the skills and character traits that should ...

Zohran Mamdani is now mayor of New York City, and the Left’s old ways of relating to elected officials won’t cut it. We need ...

When people are dropped into the most dangerous of conditions – as when disaster strikes, or during exploration of another ...

The companies that survive will look less like pyramids and more like swarms: small, autonomous AI-first pods that move and ...

SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

MIT researchers have developed a new method for designing 3D structures that can be transformed from a flat configuration ...